Advances in the Treatment of Pulmonary Hypertension

At the conclusion of this session, the participant should be able to:

1. Summarize the current guideline-directed treatment strategies for pulmonary arterial hypertension (PAH), including risk stratification and stepwise therapy escalation.
2. Evaluate the mechanisms, indications, and clinical applications of available PAH therapies, including prostacyclin analogs, PDE5 inhibitors, endothelin receptor antagonists, and emerging agents like sotatercept.
3. Apply individualized treatment planning based on patient risk profiles, comorbid conditions, and response to therapy, incorporating multidisciplinary care and monitoring tools such as echocardiography and right heart catheterization.

ACCREDITATION

The Pennsylvania Osteopathic Medical Association (POMA) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. POMA designates this activity for a maximum of 1 Category 1-A AOA CME credits and will report CME and specialty credits to the AOA commensurate with the extent of the physician’s participation in this activity.

GRIEVANCE POLICY STATEMENT

It is the policy of the POMA that any physician dissatisfied with the CME program will be issued a refund upon request, and no CME credits will be reported to the AOA.  Complaints on Evaluation Forms are also taken into consideration when planning future CME programs and may lead to changes in the format or content."  If you have any questions or concerns about this educational experience, you may call the POMA office at (717) 939-9318 or send an email message to cme@poma.org.  All questions or concerns will be addressed promptly.